N/A N=534 Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)
Pain Associated With Fibromyalgia
Primary: Percentage of Participants With Adverse Drug Reaction — 25.45 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Esthetic Outcomes of Single Immediate Implant Placement
Gingival Recession · Bone Loss, Alveolar
Primary: Change in Gingival Margin Location on the Buccal, Mesial and Distal Compared With Pre-operative Baseline and Post-operative Baseline — .11; .43; .28; .48 mm
Phase 2 N=176 Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
Chronic Plaque Psoriasis
Primary: Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12 — 6.8; 74.6; 82.8 percentage of subjects — p=<0.001
N/A N=44 Noninvasive Neuromodulation for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury
Brain Injuries, Traumatic
Primary: NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT) — 42.77; 36.24; 63.73; 62.00 score on a scale — p=0.41
Phase 2 N=80 Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
Stage V Chronic Kidney Disease
Primary: Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation — 7; 73; 3; 4 Participants — p=< 0.001
N/A N=6,009 Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)
Smoking
Primary: Count of Participants Not Smoking — 766 Participants
N/A N=48 To Assess the Mildness of a Cosmetic Cleanser in Healthy Participants Using the Forearm-Controlled Application Technique (FCAT)
Skin Care
Primary: Change From Baseline in Visual Assessment of Dryness at Day 5 — 0.48; 0.91; 0.56; 0.63 Score on a scale — p=0.1769
Phase 4 N=40 Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
Obesity, Visceral
Primary: Change in Glycerol Enrichment — 6.5; 1.4 Percentage change — p=0.0053
Phase 3 N=132 A Study With SAGE-547 for Super-Refractory Status Epilepticus
Super-Refractory Status Epilepticus
Primary: Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥…
N/A N=416 Improving Decision Making for Patients With Prolonged Mechanical Ventilation
Surrogate Decision Makers · Prolonged Mechanical Ventilation
Primary: Change in Clinician-surrogate Concordance Scale Score — -6.6; -4.8; 33.6; 34.3 score on a scale — p=<0.05
Phase 3 N=112 Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Malignant Neoplasm of Breast
Primary: Progression Free Survival (PFS) — 42; 46; 14; 10 Participants
Phase 4 N=28 Vildagliptin Versus Dapagliflozin on Glucagon
Type 2 Diabetes
Primary: Glucagon Response to Meal — 39.0; 38.8 nmol/l min
N/A N=7 Brain Metabolism in Polycystic Ovary Syndrome
Insulin Resistance
Primary: Global Brain Glucose PET Uptake — 34.9 umol/100 g/min
Early Phase 1 N=12 Role of Methane in Glycemic Control
Diabetes · Obesity
Primary: Number of Subjects Who Eradicated Methane on Breath Test — 8 participants
Phase 2 N=332 Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
Fracture Healing
Primary: Timed-Up-and-Go (TUG) Over Week 6 Through Week 20 — 54.1; 41.0; 47.2; 53.3 seconds — p=0.1983